Blocking VEGF by Bevacizumab Attenuates VEGF-Induced Vasospasm After Experimental Subarachnoid Hemorrhage in Rabbits

Aktürk, Umut Doğu; Tuncer, Cengiz; Bozkurt, Hüseyin; Şahin, Ömer Selçuk; Bulut, Hüsamettin; Arıkök, Ata Türker; Dinç, Cem; Gürer, Bora; Türkoğlu, Erhan

doi:10.1016/j.wneu.2020.03.151

Cited by 7 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specifically, adalimumab, a monoclonal antibody blocking TNF-α significantly increased the cross-sectional area of basilar arteries, reduced basilar artery wall thickness, and reduced endothelial apoptosis in rabbits with PHCV [98]. Blocking VEGF signaling with bevacizumab improved cerebral vasospasm and neurocognitive functioning following SAH in rabbits [99].…”

Section: Emerging Preclinical Treatmentsmentioning

confidence: 95%

Prevention and treatment of cerebral vasospasm following aneurysmal subarachnoid hemorrhage

McGrath,

Hey,

Ebrahim

et al. 2023

Academia Biology

View full text Add to dashboard Cite

Cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH) remains a significant cause of morbidity and mortality. Posthemorrhage cerebral vasospasm (PHCV) occurs through a complex pathophysiology, and numerous pharmacologic agents, including vasodilators, anti-inflammatories, and fibrinolytics, as well as endovascular techniques have been used to prevent and/or treat PHCV. Nimodipine continues to be the only agent with level 1 evidence, but other vasodilators have demonstrated promising results. Endovascular therapy likely has a role in treating severe/refractory PHCV, but randomized trials are needed to establish stronger evidence for this therapy. Numerous preclinical investigations highlight novel targets related to the immune response that could prove effective at improving outcomes in clinical trials. Further investigation of the glymphatic system and its role in PHCV pathogenesis could result in novel pharmacologic targets. Future trials of these therapies and combinations of existing therapies are needed, and functional outcomes should be included as an endpoint. Further exploration of the neuroinflammatory reaction following aSAH will continue to identify targetable molecules involved in PHCV pathogenesis.

show abstract

Section: Emerging Preclinical Treatmentsmentioning

confidence: 95%

Prevention and treatment of cerebral vasospasm following aneurysmal subarachnoid hemorrhage

McGrath,

Hey,

Ebrahim

et al. 2023

Academia Biology

View full text Add to dashboard Cite

show abstract

“…As a key determinant of vascular proliferation and wall thickening, VEGF has been targeted as a potential contributor to EBI and vasospasm. Bevacizumab, an anti-VEGF antibody, has been reported to reduce cerebral vasospasm and DCI thanks to its capacity to attenuate VEGF-stimulated angiogenesis and vascular cell proliferation [101]. As anti-VEGF treatments are known to be associated with cardiovascular toxicity and increased risk in thromboembolic events, further trials are needed to define the benefits from treatment [102].…”

Section: Metalloproteinase-9 and Vascular Endothelial Factormentioning

confidence: 99%

Immunological Profile of Vasospasm after Subarachnoid Hemorrhage

Romoli

Giammello

Mosconi

et al. 2023

IJMS

View full text Add to dashboard Cite

Subarachnoid hemorrhage (SAH) carries high mortality and disability rates, which are substantially driven by complications. Early brain injury and vasospasm can happen after SAH and are crucial events to prevent and treat to improve prognosis. In recent decades, immunological mechanisms have been implicated in SAH complications, with both innate and adaptive immunity involved in mechanisms of damage after SAH. The purpose of this review is to summarize the immunological profile of vasospasm, highlighting the potential implementation of biomarkers for its prediction and management. Overall, the kinetics of central nervous system (CNS) immune invasion and soluble factors’ production critically differs between patients developing vasospasm compared to those not experiencing this complication. In particular, in people developing vasospasm, a neutrophil increase develops in the first minutes to days and pairs with a mild depletion of CD45+ lymphocytes. Cytokine production is boosted early on after SAH, and a steep increase in interleukin-6, metalloproteinase-9 and vascular endothelial growth factor (VEGF) anticipates the development of vasospasm after SAH. We also highlight the role of microglia and the potential influence of genetic polymorphism in the development of vasospasm and SAH-related complications.

show abstract

“…Recent papers have documented the impact of training in nearly 33% to 74% of their respondents during this pandemic. 1 , 2 , 3 , 12 , 13 , 24 , 25 , 26 , 27 …”

Section: Introductionmentioning

confidence: 99%

Hybrid Workshops During the COVID-19 Pandemic—Dawn of a New Era in Neurosurgical Learning Platforms

et al. 2022

View full text Add to dashboard Cite

Background During the COVID-19 pandemic, disruption of surgical hands-on training has hampered the skills acquisition by budding neurosurgeons. Online and virtual classrooms have not been able to substitute the hands-on experience and learning via direct interaction with senior colleagues. To overcome these challenges, we organized a hybrid workshop where simulation-based learning modules, and direct and virtual interaction with surgeons during live surgeries or didactic lectures were utilized to help delegates in understanding the nuances of neurosurgery. Methods A 3-day hybrid workshop was held in March 2021, which was attended by 133 delegates. A structured questionnaire was utilized to record their feedback. Results An overwhelming majority of the respondents (94.1%, n = 64) found hybrid conferences to be better than an online conference. Most of the respondents (88.3%, n = 60) rated the utility of direct face-to-face interaction to be more satisfying as compared with online interaction with faculty during a webinar. Again, many the respondents (86.8%, n = 59) believed that similar hybrid events will be the new normal given the current situation of COVID-19 pandemic. A large majority (88.2%, n = 60) of the respondents reported that they will prefer a hybrid event over an online conference. Conclusions In this era of the COVID-19 pandemic, “hybrid” microneurosurgery workshops offer unique opportunities to enhance surgical skills acquisition by hands-on simulation-based learning and observing live surgical demonstrations, apart from 2-way interactions with experts under one roof. This may be a stepping stone for what lies ahead in the future of neurosurgical training.

show abstract

Blocking VEGF by Bevacizumab Attenuates VEGF-Induced Vasospasm After Experimental Subarachnoid Hemorrhage in Rabbits

Cited by 7 publications

References 24 publications

Prevention and treatment of cerebral vasospasm following aneurysmal subarachnoid hemorrhage

Prevention and treatment of cerebral vasospasm following aneurysmal subarachnoid hemorrhage

Immunological Profile of Vasospasm after Subarachnoid Hemorrhage

Hybrid Workshops During the COVID-19 Pandemic—Dawn of a New Era in Neurosurgical Learning Platforms

Contact Info

Product

Resources

About